Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
WDB coco Co., Ltd. specializes in the development and manufacturing of specialty pharmaceuticals, particularly focusing on generic drugs in Japan. The company benefits from a robust pipeline of products and a strong distribution network, which positions it favorably in a competitive market characterized by regulatory challenges and pricing pressures.
WDB coco generates revenue primarily through the sale of generic pharmaceuticals, leveraging its established relationships with healthcare providers and pharmacies. The company possesses significant pricing power due to its strong brand recognition and regulatory approvals, which create barriers to entry for competitors.
Changes in regulatory approval timelines for new drugs
Market share shifts in the generic drug segment
Pricing pressures from competitors
New product launches
Regulatory changes impacting drug approval processes
Technological disruptions in drug manufacturing
Intensifying competition from both domestic and international generic manufacturers
Potential for price erosion in key product lines
Low liquidity risk due to a high current ratio of 7.80
Dependence on a limited number of key products for revenue
moderate - The healthcare sector is generally resilient, but demand for pharmaceuticals can be affected by overall economic conditions and consumer spending.
The company's low debt levels (Debt/Equity of 0.02) mean that rising interest rates have minimal direct impact on financing costs, but could affect overall market sentiment and valuation multiples.
minimal
value - The company is currently undervalued based on its low Price/Sales and Price/Book ratios.
low - The stock has shown historical stability with a beta below 1.